Month: December 2020

VANCOUVER, British Columbia, Dec. 15, 2020 (GLOBE NEWSWIRE) — Integra Resources Corp. (“Integra” or the “Company”) (TSX-V:ITR; NYSE American:ITRG) announces that it has granted a total of 285,683 options, 358,203 restricted share units and 87,500 deferred share units (together the “Equity Incentive Awards”) to various employees, executives, directors and consultants of the Company. The Equity Incentive Awards have been granted pursuant to the Company’s Equity Incentive Plan and are subject to vesting provisions. The options have an exercise price of $4.71 per share and will expire five years from the date of grant.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.About Integra...

VANCOUVER, British Columbia, Dec. 15, 2020 (GLOBE NEWSWIRE) — The Keg Royalties Income Fund (the “Fund”) (TSX: KEG.UN) is pleased to announce that all of the nominees listed in its information circular dated November 2, 2020 were elected as trustees of the Trust at its annual meeting of unitholders held on December 15, 2020 (the “Meeting”). The results of the voting for each nominee are as follows:In addition, the Fund reports that the appointment of KPMG LLP as the Fund’s auditors for the 2020 fiscal year was passed by a majority of the votes represented at the Meeting.About The Keg Royalties Income FundThe Fund is a limited purpose, open-ended trust established under the laws of the Province of Ontario that, through The Keg Rights Limited Partnership, a subsidiary of the Fund, owns certain trademarks and other related intellectual...

CALGARY, Alberta, Dec. 15, 2020 (GLOBE NEWSWIRE) — Cenovus Energy Inc. (TSX: CVE) (NYSE: CVE) and Husky Energy Inc. (TSX: HSE) are pleased to announce that securityholders from both companies have voted to support the proposed transaction, announced October 25, 2020, to combine the two companies into a resilient integrated energy leader.On December 15, 2020, Cenovus and Husky held separate special shareholder meetings via live webcast. Each company’s securityholders, respectively, voted on resolutions in connection with the proposed business combination as described in the Joint Management Information Circular dated November 9, 2020.At the Cenovus special meeting, the resolution authorizing the issuance of Cenovus common shares and warrants to Husky common shareholders under the Plan of Arrangement, as set out in the Joint Management...

CALGARY, Alberta, Dec. 15, 2020 (GLOBE NEWSWIRE) — Cenovus Energy Inc. (TSX: CVE) (NYSE: CVE) and Husky Energy Inc. (TSX: HSE) are pleased to announce that securityholders from both companies have voted to support the proposed transaction, announced October 25, 2020, to combine the two companies into a resilient integrated energy leader.On December 15, 2020, Cenovus and Husky held separate special shareholder meetings via live webcast. Each company’s securityholders, respectively, voted on resolutions in connection with the proposed business combination as described in the Joint Management Information Circular dated November 9, 2020.At the Cenovus special meeting, the resolution authorizing the issuance of Cenovus common shares and warrants to Husky common shareholders under the Plan of Arrangement, as set out in the Joint Management...

NEW HAVEN, Conn., Dec. 15, 2020 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC® Discovery Engine, today announced the pricing of an underwritten public offering of 5,714,286 shares of its common stock at a price of $70.00 per share, before underwriting discounts and commissions. In addition, Arvinas has granted the underwriters an option for a period of 30 days to purchase up to an additional 857,142 shares of common stock at the public offering price, less the underwriting discounts and commissions. All of the shares are being offered by Arvinas.Goldman Sachs & Co. LLC and Piper Sandler & Co. are acting as joint book-running managers for the offering. Cantor Fitzgerald & Co. and BMO Capital...

NEW YORK, 15 déc. 2020 (GLOBE NEWSWIRE) — Cellectis (Euronext Growth : ALCLS – Nasdaq : CLLS), une société biopharmaceutique spécialisée dans le développement d’immunothérapies fondées sur des cellules CAR-T allogéniques ingéniérées (UCART), annonce le retrait de son offre d’American Depositary Shares (« ADS ») en raison des conditions de marché.La Société estime qu’il n’est pas dans le meilleur intérêt de ses actionnaires d’augmenter son capital dans les conditions actuelles du marché. Cellectis reste bien capitalisée avec une trésorerie à la fin du troisième trimestre 2020 de 3081 millions de dollars pour financer ses programmes clés jusqu’en 2022.Cellectis est bien positionnée sur tous les fronts et toute l’équipe demeure fidèle à sa mission de développer des produits candidats innovants au...

NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) — Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced that it has withdrawn the proposed underwritten offering of American Depositary Shares (“ADS”) due to market conditions.The Company believes that it is not in the best interest of its stockholders to raise the equity capital in the current market environment. Cellectis remains well capitalized with a cash position at the end of the third quarter of 2020 of $3081 million to fund its key programs into 2022.Cellectis is well positioned on all fronts, and the entire team remains steadfast in its mission to develop innovative product candidates to benefit cancer patients.About CellectisCellectis...

The Committee voted 12 to 1 that the data presented support the use of Entresto in treatment of patients with heart failure with preserved ejection fraction (HFpEF)Potential Q1 2021 sNDA approval could make Entresto the first therapy indicated for use in treatment of patients with both major types of chronic heart failure: HFpEF and HFrEF; and the only chronic heart failure treatment studied in both conditions against active comparators1,2HFpEF patients currently have no approved treatment options and face worsening symptoms that result in frequent HF hospitalizations, emergency room and urgent office visits1,3,4Basel, December 16, 2020 — Novartis today announced that the US Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 12 to 1 that the data presented support the use of Entresto® (sacubitril/valsartan)...

THUNDER BAY, Ontario and TORONTO, Dec. 15, 2020 (GLOBE NEWSWIRE) — PREMIER GOLD MINES LIMITED (“Premier”) (TSX:PG) (OTCPK: PIRGF) and CENTERRA GOLD INC. (“Centerra”) (TSX: CG) are pleased to announce that an affiliate of the Orion Mine Finance Group (“Orion”), has entered into an agreement (the “Purchase Agreement”) with Centerra and Premier pursuant to which Orion will acquire Centerra’s 50% interest in the Greenstone Gold Mines Partnership (“GGM”) for cash consideration of US$225 million (subject to certain adjustments) plus certain contingent payment obligations of approximately US$75 million (assuming a US$1,500 gold price), described below (the “Transaction”). Premier currently owns the other 50% of GGM.GGM’s principal asset is the Hardrock Mine Project (“Hardrock” or the “Project”) located on...

NE PAS DIFFUSER SUR LES FILS DE PRESSE AMÉRICAINS NI DISTRIBUER AUX ÉTATS-UNISMONTRÉAL, 15 déc. 2020 (GLOBE NEWSWIRE) — Air Canada (TSX : AC) (la « Société ») a annoncé aujourd’hui avoir entamé un placement public commercialisé et négocié hors séance d’actions à droit de vote variable de catégorie A et/ou d’actions à droit de vote de catégorie B (les « actions ») censé rapporter un produit brut d’environ 850 millions de dollars canadiens (le « placement »).La Société a l’intention d’accorder aux preneurs fermes une option, pouvant être exercée en totalité ou en partie dans les 30 jours suivant la clôture du placement, leur permettant d’acheter jusqu’à 15 % d’actions supplémentaires dans le cadre du placement.Le prix du placement sera établi en fonction du marché. Le prix et les modalités définitives du placement d’actions seront...